New Update Available on the New LIVE Reg. A+ Page. 

Click Here to See New Update

Go to Live Investor Page -----> https://startengine.com/med-x

Happy New Year! As we close out the end of this amazing year I wanted to take some time and reflect back on a few important milestones the company was able to accomplish in 2019 and then cover some important items as we start 2020. It was a very productive year and we are set up nicely to have an even more productive year in 2020.

A year in review:

• Nature-Cide products were introduced and sold to the professional turf grass industry for the first time.
• Nature-Cide’s international footprint grew with Rentokil in several new countries.
• Nature-Cide committed to a larger strategic marketing plan with the largest pest control distributors and industry publications.    
• The company launched its Acquisition Company Roll-Up Strategy and entered into talks with several targets in the pest control service arena. 
• The company signed a letter of intent and is working to close its first pest control service acquisition.  
• The company reserved the Nasdaq Symbol “MXRX”.
• Malibu Brands Pacific Pain Relief Cream was launched. 
• The company successfully closed its first Regulation A+ offering on StartEngine in June of 2019 capping the round off in the neighborhood of $7 million raised since 2016.
• The company signed with broker-dealer NMS Capital to partner on its new Regulation A+ capital raise. 
• The company launched the National Investor Network. 
• The Marijuana Times helped break the story on contaminated cannabis oil being sold on the black market. 
• Thermal-Aid products saw growth from Cardinal Health Distribution and direct-to-consumers.
• Nature-Cide delivered hundreds of samples of products to professionals in 2019 as the word spread around the world.  
• The company launched its own investment platform for its new Regulation A+ offering.
• The company surpassed its 2018 revenue in Q4 and reached its 2019 revenue goals. 

It was a challenging but satisfying year for our company. All of the support from our shareholders and partners allowed us to keep this movement going in a positive direction. The brands themselves, especially Nature-Cide, has become globally known as a premier Green Pest Control product line.

2020 is going to require everyone at the company to work harder than they have ever worked. This is the year where we pick up where we left off with direct-to-consumer sales for Thermal-Aid and explore a consumer revenue stream with Nature-Cide for the first time. Our media divisions are positioned to continue to grow especially the National Investor Network. The Equity Crowdfunding Report is already quickly positioning itself as the only media outlet using video to specifically cover the Equity Crowdfunding Markets and new private equity investors are learning about its resources. International pesticide label registration processes for many major countries are underway and we hope for this long process to be completed in 2020 opening the international flood gates for Nature-Cide. Conversations continue with our largest OTC healthcare distributor, Cardinal Health, to increase the footprint of the Thermal-Aid products as well as the introduction of the Malibu Brands Pacific Pain Relief Cream into OTC pharmacies. The company roll-up strategy is scheduled to go into overdrive as our first acquisition wraps up in legal and hopefully it will be announced in early 2020. We have several targets waiting in the wings to see how this first acquisition goes and we are hopeful other like-minded companies are going to want to be a part of this movement. NMS Capital is dedicated to continuing to support our efforts to bring in institutional partners into the mix as we continue our commitment to a listing on a national exchange when the time is appropriate. 

Without the continued support from each and every one of our shareholders we could not have made the progress we did this year. We all look forward to continuing the GREEN movement in these industries that are truly being forced to accept the changes coming. Natural products and services will have a place at the table in 2020 and many years beyond. 

The management team is committed to continuing to keep all of our shareholders apprised and updated on a regular basis, and in 2020 the team will continue to make ourselves available to all of our shareholders anytime. 

I wrapped up the year with an interview with our Chief Media Officer, Nick Philips, on the Equity Crowdfunding Report. It is a long, comprehensive interview. If you are interested in hearing more about 2019 and 2020, we cover many topics in the interview. We are all excited about the show and the buzz it is generating in the equity crowdfunding world. You can watch it by signing up, or logging in if you are already a member of the National Investor Network. 

Happy New Year!

Sincerely, 

Matthew Mills

President & COO

Video Interview

In this update, Matthew reports on how 2019 revenues have already surpassed 2018 revenues across multiple divisions as well as how its potential acquisition could lead to engagements with large scale investors. This progress has motivated Med-X Management to prepare the company accordingly, as they meet with the potential sponsors to list the company.

Please Visit New Campaign Page for New Important Full Company Update - NEW PAGE

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

A new company update is now live on the New Campaign page. 

New Page - https://www.startengine.com/med-x

To see the update please visit the new page. 

Click Here to See New Update - https://www.startengine.com/med-x 

Please Visit New Campaign Page for New Important Company Update - https://www.startengine.com/med-x

A new company update is now live on the New Campaign page. 

New Page - https://www.startengine.com/med-x

To see the update please visit the new page. 

Click Here to See New Update - https://www.startengine.com/med-x 

A new company update is now live on the New Campaign page. 

New Page - https://www.startengine.com/med-x

To see the update please visit the new page. 

Click Here to See New Update - https://www.startengine.com/med-x 

In this video update, COO, Matthew Mills, discusses the companies going forward strategy for raising capital with our investment banking partner, NMS Capital Advisors. He reveals a new version of the Malibu Brands Pacific Pain Relief Cream and also discusses the companies strategy to increase revenue via acquisitions to position the company to list on a national exchange like the Nasdaq. 

The press release can also be seen in its entirety below. 

To visit the New StartEngine Investment Page please visit the link here ---> New Page

Click Here for Video

Link to Press Release

LOS ANGELES, Aug. 15, 2019 /PRNewswire/ -- Med-X, Inc. -- On August 12, 2019, the Securities Exchange Commission (SEC) qualified Med-X, Inc. (Med-X) to begin the company's second Regulation A+ Equity Crowdfunding Offering. This time Med-X will be working with a Broker/Dealer, NMS Capital Advisors, LLC ("NMS Capital"), in selling the offering which is now live on the crowdfunding portal StartEngine.com. The company plans to also link and use its own web site resources which include, Med-X, Inc. the official company website, as well as placing links and information regarding the company's offering on its divisional and subsidiary web properties, such as Thermal-Aid, Nature-Cide, The National Investor Network, Malibu Brands and The Marijuana Times.

"Regulation A+ allows us to advertise and reach out to all investors, not just wealthy accredited investors who comprise the top few percent of the country. While we do have a large number of the wealthy accredited investors, it is our philosophy to let all of our customers who use our products and or services, our small business partners, friends, family and fans to all participate in our company mission," explained Med-X President and COO, Matthew Mills.

For this offering, while allowing the "Working Class American" to buy Med-X shares for as little as $420 for 525 shares, Med-X management and NMS Capital are working together to create a syndicated network of Broker/Dealers to accelerate the offering. This will provide Med-X with the ability to execute on immediate key growth strategies. 

For example, Med-X is in the midst of discussions and negotiations with multiple like-minded Eco-friendly pest control service companies, for strategic acquisition and or partnerships within the Nature-Cide's Service Division. This strategy is expected to fast-track the use of Nature-Cide's environmentally friendly and effective products within residential and wide-spread commercial applications nationwide. Other growth opportunities for Med-X divisions include adding new products to Nature-Cide's product line up, while expanding Malibu Brands new Pacific Pain Relief Cream to include a legal hemp CBD infused formulation version of the product, along with Thermal Aid's product lines and the Media Divisions, which includes the Marijuana Times and the new National Investor Network.

ABOUT MED-X, INC. 

Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Malibu Brands and Thermal-Aid divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand. The company's digital magazine, The Marijuana Times, publishes high quality media content for the medical cannabis community to potentially generate revenue from advertisers as well as sell industry related merchandise to consumers. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

We wanted to remind everyone that today is the last day for our current Equity Crowdfunding Offering.

At midnight tonight, our current offering at $.60 for 700 shares with a minimum investment of $420 will expire. This is the last opportunity to participate in this offering.

We wanted to thank everyone for your support and participation over the past few months. We all share a common goal and together we will continue to make a difference. We are just getting started and we look forward to the next chapter ahead.

We could not be where we are today without all of you.

Matthew Mills

In this update, Matthew discusses the end of the Malibu Brands Pacific Pain Relief Cream Indiegogo campaign as well as the end of our current Regulation A+ offering coming in 11 days. 

WATCH VIDEO HERE

A special thank you goes out to all of our shareholders and supporters who backed the Indiegogo launch of the Malibu Brands new pain cream product. Today we shipped out orders to over 200 backers. You should have received an email with your tracking information. If you did not get an email with your tracking info let us know and we will send it over to you. Everything is going out Priority Mail so you should see it early next week. When you get it please let us know! 

In the coming weeks, we plan to follow up with the group of first backers so we can get your feedback on the product. Sharing your stories is going to be critical as we roll this out to retailers. We are currently in talks with a couple of retail product brokers as well as our current relationships with distributors and OTC pharmacy buyers.

If you were not able to participate in the launch and you would still like to get a jar you can order it directly from the website. 

https://malibu-brands.com

As you saw in the video, Matthew explains that as of today there are only 11 days left on our current Regulation A+ offering. On June 29th this offering will expire. If you have questions about this please make sure to call your company representative or contact us via email or phone. Below is a link to our latest filing with the Securities Exchange Commission. 

https://www.sec.gov/Archives/edgar/data/1620704/000147793219003131/medx_1a.htm

Thanks again to everyone who participated in the cream launch as well as the continued support from all of our shareholders.

info@medx-rx.com

818-349-2870 

Have a great weekend and Happy Fathers Day to all the Fathers in our shareholder group! 

No Offer or Solicitation Securities

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Med-X, Inc. Cautionary Statement Regarding Forward-Looking Statements

There may be statements in this communication that are, or could be, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and, therefore, subject to risks and uncertainties, including, but not limited to, statements regarding Med-X, Inc. or the combined company's future financial position, sales, costs, earnings, cash flows, other measures of results of operations, capital expenditures or debt levels are forward-looking statements. Words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "forecast," "project" or "plan" or terms of similar meaning are also generally intended to identify forward-looking statements. Med-X, Inc. cautions that these statements are subject to numerous important risks, uncertainties, assumptions and other factors, some of which are beyond Med-X, Inc.'s control, that could cause Med-X, Inc. or the combined company's actual results to differ materially from those expressed or implied by such forward-looking statements. To learn more about the Risk factors, please review Med-X, Inc.'s Regulation A+ Offering Circular.